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b-Catenin-Independent Activation of TCF1/LEF1 in
Human Hematopoietic Tumor Cells through Interaction
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Abstract
The role of Wnt signaling in embryonic development and stem cell maintenance is well established and aberrations leading
to the constitutive up-regulation of this pathway are frequent in several types of human cancers. Upon ligand-mediated
activation, Wnt receptors promote the stabilization of b-catenin, which translocates to the nucleus and binds to the T-cell
factor/lymphoid enhancer factor (TCF/LEF) family of transcription factors to regulate the expression of Wnt target genes.
When not bound to b-catenin, the TCF/LEF proteins are believed to act as transcriptional repressors. Using a specific
lentiviral reporter, we identified hematopoietic tumor cells displaying constitutive TCF/LEF transcriptional activation in the
absence of b-catenin stabilization. Suppression of TCF/LEF activity in these cells mediated by an inducible dominantnegative TCF4 (DN-TCF4) inhibited both cell growth and the expression of Wnt target genes. Further, expression of TCF1
and LEF1, but not TCF4, stimulated TCF/LEF reporter activity in certain human cell lines independently of b-catenin. By a
complementary approach in vivo, TCF1 mutants, which lacked the ability to bind to b-catenin, induced Xenopus embryo axis
duplication, a hallmark of Wnt activation, and the expression of the Wnt target gene Xnr3. Through generation of different
TCF1-TCF4 fusion proteins, we identified three distinct TCF1 domains that participate in the b-catenin-independent activity
of this transcription factor. TCF1 and LEF1 physically interacted and functionally synergized with members of the activating
transcription factor 2 (ATF2) family of transcription factors. Moreover, knockdown of ATF2 expression in lymphoma cells
phenocopied the inhibitory effects of DN-TCF4 on the expression of target genes associated with the Wnt pathway and on
cell growth. Together, our findings indicate that, through interaction with ATF2 factors, TCF1/LEF1 promote the growth of
hematopoietic malignancies in the absence of b-catenin stabilization, thus establishing a new mechanism for TCF1/LEF1
transcriptional activity distinct from that associated with canonical Wnt signaling.
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alternative mechanisms are more frequently responsible for Wnt/
b-catenin constitutive up-regulation. Indeed, a Wnt autocrine
transforming activity was initially discovered in the mouse model
three decades ago [6], and we have established that this
mechanism also occurs frequently in different human cancers,
including breast cancer [7], non small cell lung cancer [8] and
sarcoma [9].
The Wnt/b-catenin, or canonical, pathway is initiated by Wntmediated coupling of the seven transmembrane domain receptor
Frizzled and the single-membrane-spanning low-density receptor-

Introduction
The Wnt/b-catenin signaling pathway plays an essential role
during embryonic development and as a major regulator of stem/
progenitor cell maintenance in a number of postnatal organs and
tissues, including the gastrointestinal tract, the skin and the
hematopoietic system [1–3]. Genetic alterations that lead to
aberrant activation of this pathway occur very commonly in
certain tumors, including colon cancer, hepatocellular carcinomas
and adrenocortical adenoma [4,5]. In other types of tumors,
PLOS Genetics | www.plosgenetics.org
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establish that ATF2 family members physically and functionally
interact with TCF1/LEF1 factors to promote target gene
expression and hematopoietic tumor cell growth. Together, our
results uncover a new mechanism that activates TCF1/LEF1
transcriptional activity independently of b-catenin and the Wnt
canonical pathway.

Author Summary
The Wnt signaling pathway plays a crucial role during
embryonic development and in the maintenance of stem
cell populations in various organs and tissues. Aberrant
activation of this pathway through different mechanisms
participates in the onset and progression of several types
of human cancers. In the presence of Wnt ligands,
stabilized b-catenin acts as a transcriptional activator to
induce the expression of target genes through binding to
the TCF/LEF family of transcription factors. Using in vitro
and in vivo models, we show that TCF/LEF proteins can be
activated independently of b-catenin through cooperation
with members of the ATF2 subfamily of transcription
factors. This novel alternative mechanism of TCF/LEF
activation is constitutively up-regulated in certain hematopoietic tumor cells, where it regulates the expression of
TCF/LEF target genes and promotes cell growth.

Results
b-catenin-independent TCF/LEF activity in hematopoietic
tumor cells
Using lentiviral wild-type (Top) and mutant (Fop) TCF/LEF
reporters, we investigated the status of Wnt signaling in cells
derived from several types of human cancer. As a result of this
screen, we identified up-regulated TCF/LEF activity in different
hematopoietic tumor cells, including Ramos, K562 and Jurkat
(Figure 1A). As shown in Figure S1A, TCF/LEF reporter levels in
these cells were comparable to those observed in solid tumor cells
exhibiting autocrine Wnt activation [8,9]. To assess the levels of
stabilized, transcriptionally active b-catenin in these same hematopoietic tumor lines, we used an approach based on the capture of
uncomplexed b-catenin with GST-E-cadherin beads [7–9].
Surprisingly, none showed detectable levels of stabilized b-catenin
(Figure 1B). It has been reported that c-catenin can also play a role
in Wnt signaling, probably through a mechanism involving
stabilization of b-catenin [42,43]. However, neither downregulation of b-catenin nor c-catenin had any effect on the
TCF/LEF reporter in Ramos and K562 cells (Figures 1C and
S1B), indicating that b-catenin and c-catenin were dispensable for
TCF/LEF transcriptional activation in these hematopoietic tumor
cells.
To gain insights into the biological relevance of this b-cateninindependent TCF/LEF activity, we tested the effects of a GFPfused DN-TCF4 in Ramos lymphoma cells using a lentiviral
tetracycline (Tet-off) inducible system. As a negative control for
these experiments, we utilized U937 lymphoma cells, which lacked
detectable constitutive TCF/LEF activity (Figure 1A). Doxycyline
withdrawal triggered expression of DN-TCF4 to a similar extent in
Ramos and U937 cells, as measured by FACS analysis (Figure 1D).
Under these conditions, DN-TCF4 expression inhibited colony
formation by Ramos cells but had no effect on U937 cells
(Figure 1E). Of note, induction of DN-TCF4 expression in Ramos
cells also reduced the mRNA levels of LEF1 and Axin 2
(Figure 1F), two well-established Wnt target genes. Consistent
with these results, DN-TCF4 also inhibited TCF/LEF reporter
activity as well as the expression of LEF1 and Axin 2 in K562
(Figures S1C and S1D). Together, these results indicated that
some hematopoietic tumor lines exhibit elevated b-cateninindependent TCF/LEF activity, which positively influences the
expression of Wnt target genes and tumor cell growth.
We extended our analysis to other hematopoietic tumor cell
lines as well as primary tumors. Several mantle cell lymphoma
lines, including Granta-519, HBL-2, JEKO-1 and JVM-2,
exhibited TCF/LEF reporter levels as high or higher than Ramos
(Figure S1E) and also contained undetectable levels of uncomplexed b-catenin (Figure S1F), implying their activation of bcatenin-independent TCF/LEF transcriptional activity. We also
surveyed a series of primary hematopoietic tumors for expression
of Axin 2 and LEF1 as compared to levels present in Ramos and
U937 cells. Several exhibited high expression levels of these TCF/
LEF target genes in the absence of detectable uncomplexed bcatenin (Figures 1G and S1G), arguing that activation of this novel
pathway was not limited to hematopoietic tumor lines but
occurred in primary human hematopoietic tumors as well.

related protein 5/6 (LRP5/6), followed by phosphorylation of the
LRP5/6 intracellular domain [10,11]. Through a mechanism not
yet fully understood, phosphorylated LRP5/6 leads to the
inhibition of the so-called b-catenin destruction complex,
composed of axin, glycogen synthase kinase 3, dishevelled (Dvl),
casein kinase 1 and the tumor suppressor adenomatous polyposis
coli, resulting in the accumulation of b-catenin in the cytoplasm
and the nucleus [11,12]. In the absence of Wnt activation, the four
members of the TCF/LEF family of transcription factors form a
complex with Groucho/TLE repressors and inhibit gene expression [3,13,14,15,16,17]. Through either direct competition [18] or
XIAP-mediated ubiquitylation [19], nuclear b-catenin displaces
Groucho/TLE and binds to TCF/LEF factors, thus promoting a
transcriptional switch that allows the expression of Wnt target
genes, including Myc, cyclin D1, Axin 2 and Lef1 [4,20].
While its role in the control of gene expression is thought to
depend mainly on the interaction with TCF/LEF proteins, bcatenin can act in some contexts through binding to other
transcription factors, including the homeodomain protein Prop1
[21], various nuclear receptors [17,22], the forkhead box O factors
[23] and the Krueppel-like factor 4 [24]. TCF/LEF factors can
also interact with other proteins, including ALY [25], Smad
[26,27] and c-Jun [28], allowing the formation of large nuclear
complexes that control the expression of genes containing a
particular combination of regulatory sequences in their promoter/
enhancer. While providing an additional level of regulation, such
interactions do not challenge the general notion that nuclear bcatenin is required for TCF/LEF transcriptional activity, which is
widely supported by biochemical and genetic data [2,15,29]. An
exception to this paradigm may involve the hematopoietic system,
where intriguing discrepancies in the phenotypes of TCF1/LEF1
and b-catenin null mice have suggested that in particular contexts
canonical Wnt signals could be transduced independently of bcatenin [30–36].
While the b-catenin pathway has been reported to be
upregulated in cancer stem cells of different leukemias [37–40]
and in the transition from chronic to acute myelogenous leukemia
[41], mutations in intracellular components that are frequently
responsible for Wnt pathway activation in solid tumors are
uncommon in hematopoietic tumors. Here we show that some
hematopoietic tumor cells display b-catenin-independent TCF/
LEF activity, whose down-regulation inhibits the expression of
TCF/LEF target genes and cell growth. Using both in vitro and in
vivo approaches, we further demonstrate that TCF1 retains
transcriptional activity in the absence of b-catenin. Finally, we
PLOS Genetics | www.plosgenetics.org
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Figure 1. Constitutive TCF/LEF activity in hematopoietic tumor cells in the absence of b-catenin stabilization. (A) The indicated
hematopoietic tumor cells were transduced with wild-type (Top) or mutant (Fop) TCF/LEF firefly luciferase reporter and a renilla luciferase virus, and
the TCF/LEF transcriptional activity was calculated by dividing the TOP/renilla ratio by the FOP/renilla ratio. The mean values (6 s.e.m., n.5) of at
least two independent experiments are shown. (B) Lack of b-catenin stabilization in K562, Jurkat and Ramos cells, as measured by GST-E-cadherin
pull-down. Ovarian PA1 cancer cells and breast immortalized AB5 cells were used as positive and negative control, respectively. (C) b-catenin or ccatenin knockdown in Ramos cells did not affect TCF/LEF activity. Ramos cells containing Top or Fop luciferase reporter were infected with b-catenin
or c-catenin shRNA and the TCF/LEF reporter activity was measured (lower panel). b-catenin and c-catenin down-regulation was assessed by
immunoblot (upper panel). (D) Ramos and U937 cells containing the tet transactivator (tTA) with or without a lentiviral inducible vector containing
DN-TCF4 fused to GFP were cultured for 24 hrs in the presence or the absence of doxycycline (dox), and the proportion of GFP positive cells was
assessed by FACS analysis. (E) The cells in D were used in colony formation assay in the presence or the absence of dox. (F) Effects of DN-TCF4
induction in Ramos cells on the expression of LEF1 and Axin 2 by quantitative real-time PCR. (G) mRNA levels of Axin 2 and LEF1 in human primary
hematopoietic tumors. For each sample, the qPCR values were normalized with those obtained for the negative control, U937 cells. The types of
malignancy corresponding to each sample are listed in the table: MCL, mantle cell lymphoma; CLL, B-cell chronic lymphocytic leukemia; splMZL,
splenic marginal zone lymphoma; FLN, follicular lymphoma; HLN, Hodgkin’s lymphoma.
doi:10.1371/journal.pgen.1003603.g001
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strictly required for this effect. To inhibit any residual nuclear bcatenin potentially present in 293T cells, we generated a decoy
construct containing the TCF1 b-catenin binding domain fused to
the Gal4 DNA binding domain (BCBD). While almost completely
abolishing the up-regulation of the TCF/LEF reporter induced by
Wnt3a (Figure 2B), BCBD did not affect TCF1 transcriptional
activity (Figure 2C), strongly arguing against the involvement of bcatenin in this activity.
Based on the crystal structure of the b-catenin-TCF3 complex,
we mutated two residues in the TCF1 b-catenin binding domain,
D21A and E29K, which should impair the ability of this
transcription factor to bind to b-catenin [47]. Figures 2D and
S3A show that this mutant, designated TCF1mt, was unable to
physically interact with b-catenin by co-immunoprecipitation and
failed to synergize with b-catenin or c-catenin to stimulate the Wnt
responsive reporter, instead exerting an antagonistic effect
(Figures 2E, S3B and S3C). In contrast, both wild type TCF1
and TCF1mt expression stimulated TCF/LEF activity in 293T
cells to similar extents (Figure 2F), implying that TCF1 was able to
act as a transcriptional activator independently of b-catenin.

TCF1 and LEF1, but not TCF4, are transcriptionally active
independently of b-catenin
TCF1 and LEF1 were cloned in 1991 from hematopoietic cells
[44–46] and belong to a four-member family of transcription
factors containing a N-terminal b-catenin binding domain and a
high mobility group DNA binding domain located closer to the Cterminus [15]. To investigate whether these factors could act as
transcriptional activators in the absence of b-catenin, we expressed
TCF1, LEF1 or TCF4 in 293T cells, which lack constitutive Wnt
activation. Figure 2A shows that TCF1 and LEF1, but not TCF4,
stimulated TCF/LEF reporter activity in these cells. The
stimulatory effect of TCF1 was observed using three different
reporter constructs, containing respectively 2, 4 and 8 TCF/LEF
repeats generated using different backbone vectors (Figure S2A).
As an additional specificity control, TCF1-induced reporter
activity was strongly inhibited by an excess of DN-TCF4 (Figure
S2B). Of note, deletion of the first 65 aa, containing the b-catenin
binding domain, only partially reduced the TCF/LEF activation
induced by TCF1 (Figure 2A), indicating that b-catenin was not

Figure 2. b-catenin-independent transcriptional activity of TCF1/LEF1 factors. (A) Empty pcDNA3HA vector or increasing amounts of HAtagged TCF1, LEF1 or TCF4 constructs were co-transfected with SuperTop or SuperFop and renilla luciferase plasmids in 293T cells and the Top/Fop
ratio was calculated. (B–C) Effects of a decoy construct containing TCF1 b-catenin binding domain (BCBD) on Wnt3a- and TCF1-induced TCF/LEF
reporter activity. 293T cells were co-transfected with SuperTop and renilla reporter plasmids, together with the Wnt3a, TCF1 and BCBD vectors as
indicated. (D–E) Mutant TCF1 (mtTCF1; D21A, E29K) is unable to bind to b-catenin. (D) 293T cells were transfected with the indicated HA-tagged TCF1
or TCF4 constructs and the myc-tagged b-catenin, followed by immunoprecipitation using anti-HA antibody and immunoblot with anti-myc or antiHA antibodies. (E) 3T3 cells were co-transfected with b-catenin, the indicated amounts of TCF1, d36TCF1 or mtTCF1, together with SuperTop and
renilla luciferase plasmids. (F) Effects of TCF1 and mtTCF1 expression on TCF/LEF reporter activity. 293T cells were co-transfected with SuperTop and
renilla luciferase plasmids and different amounts of TCF1 or mtTCF1, followed by reporter assay.
doi:10.1371/journal.pgen.1003603.g002
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Different TCF1 domains are involved in its b-cateninindependent transcriptional activity

TCF1, but not TCF4, stimulates the expression of Wnt
target genes in Xenopus laevis embryos independently of
b-catenin

To gain insights into the mechanisms responsible for b-cateninindependent TCF1/LEF1 transcriptional activity, we next investigated the contribution of different TCF1 domains to its ability to
stimulate TCF/LEF reporter activity. Alternative splicing gives
rise to several isoforms of each TCF/LEF protein, which in some
cases can affect their activity [14,15]. While the majority of these
splicing events involve the C-terminus, experiments in Xenopus
have suggested that the central exon IVa might be responsible for
the balance between the activating and repressive functions of
these transcription factors [52,53]. We found that the presence or
the absence of exon IVa did not affect TCF/LEF1 reporter
activity induced by human TCF1 in 293T cells (Figure S4),
indicating that this region is not involved in b-catenin-independent
TCF1 transcriptional activity.
It has been reported that certain C-terminal TCF splice
variants can bind to repressors, including CtBP [54], although the
biological relevance of such interactions is controversial [15,55].
To assess whether the b-catenin independent activity of
TCF1 was associated with a particular C-terminal domain, we
generated a chimeric protein containing the first 299 aa of TCF1
fused to the DNA-binding domain and C-terminus of TCF4
(TCF1/4(1–299); Figure 4A). We observed that TCF1 and

During the earliest stages of Xenopus embryonic development,
locally activated Wnt signaling induces the asymmetric expression
of genes of the dorsal organizer, thus allowing the establishment of
dorsal-ventral polarity [48–50]. We used this in vivo model to assess
the b-catenin-independent activity of TCF1. As previously
reported [51], injection of tcf1, but not tcf4, mRNA induced
ectopic expression of the Wnt direct target gene Xnr3 in animal
cap explants (Figure 3A). Of note, we found that both TCF1mt
and the N-terminal truncated TCF1 (del65TCF1) were able to
trigger Xnr3 expression, indicating that b-catenin was not required
for this effect. Under these conditions, Wnt3a, but not the TCF1
constructs, increased the expression of another organizer gene,
Chordin, likely reflecting its ability to induce a higher level of Wnt
pathway activation. As a specificity control, neither TCF1 nor
Wnt3a had an effect on the TGF-b target gene Xbra (Figure 3A).
Consistent with these data, all TCF1 constructs, but not TCF4,
induced axis duplication in the embryos (Figure 3B). Together, our
findings indicate that in the absence of b-catenin TCF1 does not
strictly act as a transcriptional repressor, but instead can stimulate
the expression of Wnt canonical target genes and functions in vivo
independently of b-catenin.

Figure 3. TCF1 activity in Xenopus laevis explants and embryos. (A) Wnt3a, wild-type and b-catenin-independent mutants of TCF1, but not
TCF4, induce expression of the canonical Wnt pathway-responsive gene Xnr3 in ectodermal (animal cap) explants. RT-PCR analysis of animal caps
dissected at late blastula stages and cultured until stage 10.5. EF1-a is used as a loading control. The –RT lane contains all reagents except reverse
transcriptase, and is used as a negative control. (B) Graph depicting embryonic perturbation by Wnt3a, TCF4, and wild-type and mutant TCF1.
Embryos were injected in the ventral marginal zone at early cleavage stages and cultured until late tailbud stages. For (A) and (B), 1 ng (TCF4 high) or
500 pg (TCF1, del65TCF1, TCF1m, TCF4low, Wnt3a) of each RNA was injected, as listed. (C) Representative embryos recorded in the graph shown in
(B). Dorsal views; anterior is to right. All embryos in (C) were injected with RNA encoding del65TCF1. Staining with the 12/101 antibody, which
recognizes a somite specific epitope, was used to assess axis duplication.
doi:10.1371/journal.pgen.1003603.g003
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Figure 4. Mapping of the TCF1 domains involved in b-catenin-independent transcriptional activity. (A) Diagram of the different
constructs used for the mapping. (B–D) 293T cells were co-transfected with the SuperTop reporter, the renilla plasmid and the indicated constructs,
followed by reporter assay two days after transfection. (B) TCF1 N-terminal domain is required, but not sufficient, for b-catenin-independent full
transcriptional activity. (C) Deletion of either aa 101–211 or 212–299 inhibits the b-catenin-independent transcriptional activity of TCF1. (D)
Transcriptional activity of two different TCF1 domains fused to the Gal4 DNA binding domain. 293T cells were co-transfected with a Gal4 responsive
reporter and the indicated TCF1-Gal4 fusion constructs, followed by reporter assay. (E) Expression of TCF1 aa 37–122, but not aa 100–211, inhibits
TCF1-induced reporter activity. 293T cells were co-transfected with the Supertop reporter and the indicated TCF1-Gal4 fusion constructs, in the
presence or the absence of TCF1, followed by reporter assay two days after transfection.
doi:10.1371/journal.pgen.1003603.g004

while aa 37–122 had no effect (Figure 4D). Of note, expression of
TCF1(37–122)-Gal4, but not TCF1(100–211)-Gal4, inhibited
TCF/LEF reporter activity induced by TCF1 in 293T cells
(Figure 4E), suggesting that TCF1(37–122)-Gal4 may interfere
with the binding to a TCF1 molecular partner, while TCF1(100–
211) may have an intrinsic transactivation activity. Together, these
results indicated that these three TCF1 domains have distinct roles
in its b-catenin independent activity: the region between aa 100–
211 is partially active on its own, while the N-terminal 100 aa and
aa 211–299 are required for full transcriptional function.

TCF1/4(1–299) stimulated the TCF/LEF reporter to a similar
extent, while TCF4 was inactive (Figure 4B), indicating that
TCF1 C-terminus and DNA binding domains were not required
for this effect. Using a similar approach, we showed that
swapping the N-terminal 100 aa of TCF1 with the corresponding
domain of TCF4 resulted in nearly inactive fusion proteins
(Figure 4B). These results implied that this region was important
for TCF1 transcriptional activity but not sufficient to confer bcatenin-independent transcriptional activity to TCF4. We
extended TCF1 mapping and found that deletion of the region
between aa 56/101 and aa 211 partially reduced TCF1
transcriptional activity in the absence of b-catenin (Figure 4C
and S5A) but had no effect on the synergy between TCF1 and bcatenin (Figure S5B). As shown in Figure 4C, a TCF1/4 fusion
protein containing TCF1 aa 1–211 and the TCF4 DNA binding
domain and C-terminus showed decreased TCF/LEF activity,
implying that aa 212–299 are also involved in b-cateninindependent TCF1 activity.
As a complementary approach, we assessed the activity of
different TCF1 domains fused to the Gal4 DNA binding domain.
Consistent with the results shown in Figures 4B and 4C, TCF1 aa
100–211 strongly up-regulated the activity of a Gal4 reporter,
PLOS Genetics | www.plosgenetics.org

ATF2 transcription factors cooperate with TCF1/LEF1 to
promote the growth of hematopoietic tumor cells
We used a candidate approach to identify partners for TCF1/
LEF1 potentially involved in their b-catenin independent activity. It
has been shown that c-Jun binds to TCF4 and b-catenin to promote
intestinal cancer development [28]. We tested the effects of TCF1
and c-Jun co-expression in 293T cells and found that c-Jun actually
decreased TCF1-induced reporter activity (Figure 5A). A similar
inhibitory effect was observed upon expression of the c-Jun-related
JunB (Figure 5A), indicating that the c-Jun family has opposite
effects in b-catenin-dependent and b-catenin-independent TCF/
6
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of transcription factors. Indeed, expression of the two other ATF2like proteins, i.e. activating transcription factor 7 (ATF7) and cAMP
responsive element binding protein 5 (CREB5), also increased the
TCF/LEF transcriptional activity of TCF1 and LEF1 (Figures 5D,
5E and 5F). Consistent with our previous findings, TCF4 was
unable to stimulate the TCF/LEF reporter even in the presence of
overexpressed ATF2, CREB5 or ATF7 (Figure S7A). Of note,
various combinations of TCF1/LEF1 and ATF2 factors displayed
different degrees of cooperation, with TCF1-ATF2 and LEF1CREB5 showing the strongest synergy, likely reflecting preferential
interactions among distinct members of these two transcription
factor families.
To gain insights into the mechanisms involved in the synergistic
functional interactions of TCF1/LEF1 and ATF2, we investigated

LEF signaling. These results prompted us to investigate the effects of
other activator protein-1 (AP-1) factors and Jun binding partners on
TCF1 transcriptional activity. While c-Fos had no effect (data not
shown), ATF2 strongly synergized with TCF1 in stimulating the
TCF/LEF reporter (Figure 5B). Of note, expression of ATF2 alone
moderately increased reporter activity (Figure 5B), presumably
through endogenous TCF1/LEF1. ATF2 showed a similar
synergistic effect when co-expressed with TCF1mt, as well as in
the presence of either Dvl or b-catenin shRNA (Figure S6), implying
that the cooperation between TCF1 and ATF2 was independent of
b-catenin. The fact that ATF2 also enhanced LEF1-induced
reporter activity (Figure 5C) suggested that the synergy we
uncovered between TCF1 and ATF2 could be part of a more
general cooperation between the TCF1/LEF1 and ATF2 families

Figure 5. ATF2 transcription factors cooperate with TCF1/LEF1 to stimulate TCF/LEF activity. (A–F) 293T cells were co-transfected with
the Supertop reporter, the renilla plasmid and the indicated TCF/LEF or AP1 transcription factors, followed by TCF/LEF reporter assay two days after
transfection. (A) c-Jun and JunB inhibition of TCF1-induced reporter activity. (B–C) ATF2 synergizes with TCF1 (B) and LEF1 (C) to increase TCF/LEF
activity. (D) ATF7 enhances TCF1- and LEF1-induced reporter activity. (E–F) CREB5 cooperated with TCF1 (E) and LEF1 (F). (G) myc-tagged LEF1 coimmunoprecipitates with Flag-tagged CREB5 in 293T cells. (H) Endogenous ATF2 co-immunoprecipitates with Flag-tagged TCF1 in 293T cells. Cells
transduced with lentiviral shATF2 were used as a negative control and immunoblot with anti-Axin antibody was used as loading control for the total
lysate.
doi:10.1371/journal.pgen.1003603.g005
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regulation of TCF/LEF activity identified in some human
hematopoietic tumor lines. We observed that shRNA-mediated
down-regulation of ATF2 and ATF7 in Ramos cells significantly
inhibited their endogenous TCF/LEF reporter activity (Figure 6A),
as well as the expression of the Wnt target gene Axin 2 (Figure 6B).
Consistent with our results using DN-TCF4 (Figure 1), the
repression of TCF/LEF transcriptional activity induced by
shATF2/7 in these cells was accompanied by inhibition of colony
formation (Figure 6C). Together, our results provide compelling
evidence for a new mechanism of constitutive TCF/LEF
activation in tumor cells, which is independent of b-catenin and
involves cooperation with ATF2 transcription factors.

the ability of these proteins to form complexes. LEF1 formed a
complex with CREB5 (Figure 5G), and TCF1 did so with
endogenous ATF2 in 293T cells (Figure 5H), while coupling
between endogenous LEF1 and ATF2/ATF7 was observed in
Ramos and K562 cells (Figure S8). Of note, TCF4 showed weaker
interaction with CREB5 compared to TCF1 (Figure S7B),
suggesting that TCF4’s lack of transcriptional activity could reflect
a lower binding affinity for ATF2 factors. These findings indicated
that TCF1/LEF1 proteins interact physically as well as functionally with ATF2 transcription factors.
Finally, we asked whether the association between TCF1/LEF1
and ATF2 factors plays a role in the b-catenin-independent up-

Figure 6. ATF2 and ATF7 knockdown in Ramos cells decreases TCF/LEF activity, Axin 2 expression and cell growth. (A–C) Ramos cells
containing the TCF/LEF firefly and renilla luciferase lentiviral reporters were transduced with shATF2 and shATF7 or control lentiviral vectors. ATF2
and ATF7 down-regulation assessed by immunoblot analysis. (A) shATF2/7 inhibits constitutive TCF/LEF reporter activity in Ramos cells. (B)
Knockdown of ATF2 and ATF7 reduces the expression of the Wnt target gene Axin 2 in Ramos cells as measured by quantitative real-time PCR. The
results normalized to the control represent the mean values 6 SEM of three independent experiments. (*) P,0.05; (**) P,0.001 compared with
control (two-way Anova test) (C) shATF2/7 inhibits Ramos cell colony formation. (D) Model for b-catenin-dependent and b-catenin-independent
canonical Wnt signaling. See the text for details.
doi:10.1371/journal.pgen.1003603.g006
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independent transcriptional activity, suggesting that the induction
of such tumors might be due to this activity rather than to
inhibition of Wnt canonical signaling.
We established that both TCF1 and LEF1 interact with ATF2
transcription factors to promote TCF/LEF activity, and inhibition
of such activity using either DN-TCF4 or shATF2/7 decreased
the expression of Wnt target genes, as well as lymphoma cell
growth. The role of ATF2 proteins in cancer depends on cell
context, as these factors have been associated with both oncogenic
or tumor suppressive functions [61]. Contrary to what was
previously reported for the b-catenin-TCF4 complex [28], we
found that c-Jun and JunB inhibited TCF1-induced transcription,
suggesting that Jun proteins may compete with TCF1/LEF for
binding to ATF2. While c-Jun is an oncogene overexpressed or
amplified in different types of cancer, including sarcomas [61], it
has been demonstrated that conditional JunB inactivation [62,63]
or PU.1 related downregulation of both JunB and c-Jun [64]
provoke myeloproliferative disorders and different types of
leukemia in mice. It is tempting to speculate that decreased levels
of JunB and/or c-Jun may perturb the balance between different
AP1 factors, thus facilitating the interaction between ATF2 and
TCF1/LEF1.
With the exception of few general target genes, including LEF1
and Axin 2, the transcriptional outcome of activated Wnt signaling
depends on the cell/tissue context. Gene array experiments have
identified hundreds of genes whose expression is modified by Wnt,
with often little overlap between different cell models [15]. A
number of variables likely contribute in determining which genes
are regulated in a particular cell or tissue type, including the
strength of the signal, cooperation with other pathways or
transcription factors, expression of different LEF/TCF isoforms
[65] and, possibly, even post-translational modifications of TCF/
LEF factors [66,67]. We showed that down-regulation of bcatenin-independent TCF/LEF activity inhibited the expression of
LEF1 and Axin 2 genes. However, further studies will be needed to
obtain a broader view of the genes regulated through this new
mechanism of TCF/LEF activation and to assess similarity and
differences with classical Wnt/b-catenin signaling. In a recent
study, TCF1 was identified as one of the most up-regulated genes
in self-renewing versus partially differentiated hematopoietic
multipotential precursor cells [68]. These same authors found by
ChIP-seq that TCF1 primarily binds to up-regulated genes, many
of which are involved in self-renewal [68]. Yet, expression of Wnt
ligands was extremely low in these cells, consistent with activation
of TCF1 being independent of b-catenin and canonical Wnt
signaling. The integration of this type of high-throughput dataset
with those generated in other systems, in which the Wnt canonical
pathway is active, may aid in dissecting the different functions of bcatenin-dependent and -independent TCF/LEF signaling.

Discussion
In the present study, we uncovered a novel mechanism of TCF/
LEF dependent transcription that bypasses b-catenin and increases
expression of Wnt target genes through interaction of TCF1/
LEF1 and ATF2 transcription factors (Figure 6D). We utilized
several different approaches, including shRNA and decoy
constructs, as well as TCF1 mutants unable to bind to b-catenin,
to demonstrate that TCF1/LEF1 possess transcriptional activity
that is independent of b-catenin. Expression of these proteins was
able to stimulate the TCF/LEF reporter in mammalian cells, and
to trigger Wnt target genes in vivo, accompanied by induction of
the characteristic axis-duplication phenotype in Xenopus embryos.
We showed further that this mode of TCF/LEF activation in the
absence of b-catenin stabilization occurs constitutively in some
human hematopoietic tumors, where it plays a role in stimulating
cell growth. Thus, this cooperation between TCF1/LEF1 and
ATF2 represents an unexpected new strategy used by tumor cells
to aberrantly activate TCF1/LEF1 signaling independently of bcatenin and the Wnt canonical pathway.
Several arguments support a role of TCF/LEF dependent Wnt
signaling in the hematopoietic system [56], and it has recently been
shown that moderate levels of canonical Wnt activation promote the
function and/or the maintenance of various hematopoietic lineages
[57]. However, the involvement of b-catenin in these cells is highly
controversial [56]. While the knock-out of TCF1 and/or LEF1
demonstrated that these transcription factors are required for
normal T and B cell development [30–32], b-catenin conditional
deletion in the mature hematopoietic system using different CRE
drivers only showed mild [37] or undetectable effects [33,36]. In
fact, using two different Wnt responsive gene reporters, Jeannet et
al. demonstrated that thymocytes exhibited constitutive TCF/LEF
activity, which was strongly inhibited upon knock-out of TCF1, but
not b-catenin or c-catenin [34]. In light of our present findings, it is
tempting to speculate that this new mechanism of b-cateninindependent activation of TCF1/LEF1 identified by us here may
allow a cell autonomous up-regulated level, required for the
maintenance of certain hematopoietic lineages.
We identified three TCF1 domains involved in b-cateninindependent activity, all of which localized N-terminally of the
high mobility group DNA binding domain. Whereas the region
between aa 100 and 211 displayed some intrinsic transactivation
properties when fused to the Gal4 DNA binding domain, the Nterminal 100 aa proved to be particularly important, albeit not
sufficient, to confer transcriptional activity to TCF1. The Nterminal domain of TCF/LEF proteins has been previously
associated with binding to b-catenin [14,15,47], and our
demonstration that this region also participates in b-cateninindependent signaling may help in the interpretation of several
previous observations. For example, it has been assumed that
binding to b-catenin is required for the role of TCF1 in T cell
development, since the defects in thymocyte maturation and
survival observed in TCF1 null mice could be rescued by
expression of the long TCF1 isoform, but not using a short
TCF1 lacking the N-Terminal 116 aa [58]. The fact that the Nterminal 100 aa of TCF1 also participate in its b-cateninindependent transcriptional activity may help to reconcile these
findings with the normal phenotype of b-catenin null thymocytes
[33–35]. Human sebaceous tumors have been reported to contain
LEF-1 N-terminal domain mutations with decreased ability to
interact with b-catenin [59], and expression of a LEF1 construct
lacking the first 32 aa driven by the keratin 14 promoter provoked
the formation of sebaceous skin tumors in mice [60]. Our results
indicate that N-terminally deleted LEF1 should retain b-catenin
PLOS Genetics | www.plosgenetics.org

Materials and Methods
Cell culture, transfection and lentivirus production
Ramos (Burkitt’s lymphoma), U937 (histiocytic lymphoma),
K562 (chronic myelogenous leukemia) and Jurkat (acute T-cell
leukemia) cells were maintained in RPMI-1640 (Lonza) supplemented with 10% fetal bovine serum (FBS; Sigma). Human
mantle cell lymphoma lines including Granta-519, HBL-2, JEKO1 and JVM-2 were generously provided by Dr. Samir Parekh,
Icahn School of Medicine at Mount Sinai, and were also cultured
in this medium. AB5 (immortalized human breast epithelial), PA1
(ovarian teratocarcinoma), 293T (human embryonic kidney),
NIH-3T3 (mouse fibroblasts) and Mel888 (melanoma) cells were
maintained in DMEM (Lonza) supplemented with 10% FBS.
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Transient transfection was performed using Fugene 6 (Roche)
according to the manufacturer’s instructions or with polyethylenimine (Polysciences). For lentivirus production, 293T cells were
co-transfected with the lentiviral vector, pCMV D8.91 and pMD
VSV-G plasmids. The conditioned medium containing the viral
particles was collected two, three and four days after transfection,
supplemented with 8 mg/ml polybrene and added to a pellet of
hematopoietic tumor cells, followed by centrifugation for 1 h at
500 g, 4uC and overnight incubation at 37uC, 5% CO2. Two days
after transduction, the cells were selected in 2 mg/ml puromycin or
10 mg/ml blasticidin.

(Sigma), rabbit anti-ATF2, rabbit anti-HA (Santa Cruz), goat
anti-Axin (R&D Systems), rabbit anti-ATF7 (Abcam), mouse antiLEF1 (Millipore). Mouse anti-myc clone 9E10 was obtained from
the Mount Sinai Hybridoma Core Facility.
For immunoblot, cells were washed once with phosphatebuffered saline (PBS) and lysed on ice in lysis buffer containing
50 mM Hepes pH 7.6, 150 mM NaCl, 5 mM EDTA, 1%
Nonidet P-40, 20 mM NaF, 2 mM sodium orthovanadate,
supplemented with the Complete Mini proteinase inhibitor
cocktail tablets (Roche). Lysates were cleared by centrifugation
at 20,0006 g for 15 min at 4uC and protein concentrations were
determined by using the Bio-Rad protein assay (Bio-Rad). Sodium
dodecyl sulfate (SDS) loading buffer was added to equal amounts
of lysate, followed by SDS-polyacrylamide gel electrophoresis
(SDS-PAGE) and transfer to Immobilon-P membranes (Millipore).
Antibodies used in immunoblot analysis were revealed by
chemiluminescence using ECL Western Blotting Substrate
(Thermo Fisher Scientific) or using the Odyssey Infrared Imaging
System (LI-COR Biotechnology). For immunoprecipitation, equal
amounts of cell lysates were incubated either with anti-Flag M2
agarose beads (Sigma) for 3 hrs at 4uC or with mouse anti-myc or
mouse anti-HA antibodies for 1 hr at 4uC, followed by 3 hr
incubation with Protein G Sepharose 4 Fast Flow beads (GE
Healthcare). For LEF1 immunoprecipitation, equal amounts of
cell lysates were incubated with aLEF1 antibody for 2 hrs at 4uC,
followed by overnight incubation with Protein G Sepharose 4 Fast
Flow beads. Beads were washed three times with lysis buffer and
resuspended in SDS loading buffer, followed by SDS-PAGE and
immunoblot.

Primary human hematopoietic tumor cells
Primary human lymphoma samples were obtained either as part
of standard excisional biopsy or from peripheral blood samples
from patients at the Icahn School of Medicine at Mount Sinai with
informed consent reviewed and approved by the Institutional
Review Board and in accordance with the Declaration of Helsinki.
Specimens were processed to viable, sterile single-cell suspensions.
Briefly, lymph node tissue was diced and forced through a metal
sieve in a laminar flow hood into RPMI tissue culture medium.
Peripheral blood mononuclear cells or disaggregated follicular
lymphoma biopsy cells were pelleted by low-speed centrifugation,
resuspended in media composed of 90% fetal calf serum and 10%
DMSO (Sigma), frozen slowly in the vapor phase of liquid
nitrogen in multiple cryotubes, and stored in liquid nitrogen. The
frozen cells were thawed and maintained for 1–3 days in RPMI1640 supplemented with 10% fetal bovine serum prior to RNA
extraction for qPCR analysis or preparation of cell lysates for
analysis of uncomplexed b-catenin (see below).

Free b-catenin and reporter assays

Constructs

Uncomplexed b-catenin was measured using glutathione Stransferase (GST)–E-cadherin or GST-TCF1 beads as described
previously [70]. Briefly, bacterially expressed E-cadherin or TCF1
b-catenin binding domains fused to GST were bound to
glutathione-Sepharose beads (GE Healthcare) and incubated with
equal amounts of cell lysates. After pull-down, the samples were
subjected to immunoblot analysis using anti-b-catenin antibody.
For luciferase reporter assay, the cells were transfected or
transduced with the TCF/LEF firefly luciferase reporters and
the renilla luciferase control reporters or transfected with the Gal4
responsive vector pG5luc (Promega) and the renilla containing
pBind plasmid. The cells were lysed and luciferase activity was
measured using the Dual-Luciferase Reporter Assay System
(Promega) according to the manufacturer’s instructions. For GFP
reporter assay, cells transduced with the Top or Fop TCF/LEF
GFP reporter were transferred to polystyrene tubes (Falcon) and
subjected to FACS analysis (FACScan; Becton Dickinson) using
CellQuest 3.2 software (Becton Dickinson).

Lentiviral TCF/LEF luciferase and GFP reporters, b-catenin and
Dvl shRNAs, inducible and constitutive DN-TCF4 vectors and the
SuperTop reporter (pTA-Luc vector) were previously described
[8,69]. The pOT (pGL3) reporter was kindly provided by B.
Vogelstein. The Top-Glow reporter was purchased from Millipore.
Human TCF4 was cloned by PCR from 293T cells into
pcDNA3HA vector. Human TCF1 was cloned from CCRFCEM cells into pcDNA3HA and pcDNA3flag vectors. TCF1
mutant (D21A; E29K) was generated using the QuikChange SiteDirected Mutagenesis Kit (Stratagene). TCF1 N-terminal deletion
and TCF1-TCF4 fusion constructs were generated by PCR in
pcDNA3HA. The sequence corresponding to TCF1 b-catenin
binding domain (N-terminal 60 aa), aa 37–122 and aa 100–211
were cloned downstream of Gal4 DNA binding domain into the
pBIND vector from the CheckMate Mammalian Two-Hybrid
System (Promega). Full-length LEF1 was cloned in pCAN-myc2
and pcDNA3HA (Figure 2A) vectors. Myc-tagged b-catenin and
HA-tagged Wnt3a were cloned into pCCBS vector. Human ATF2
and CREB5 were cloned into pEF-flag vector. c-Jun and Jun-B
were cloned into pcDNA3HA. The ATF7 construct was kindly
provided by P.J. Hamard. The lentiviral shRNA constructs
targeting b-catenin, c-catenin, ATF2 and ATF7 were generated
in VIRDH-EP or VIRHD-bla vectors, using the following targeting
sequences: GTACGAGCTGCTATGTTCC (b-catenin), CACCATTCCCCTGTTTGTG (c-catenin), AGCCCTCAGGAAGTTGATTAAA (ATF2) and CGAAGAACTCACTTCTCAGAA
(ATF7). All constructs were sequence verified.

Colony forming assay
Growth of hematopoietic tumor cells in soft agarose was
determined by seeding 26103 cells per 60-mm dish in 0.5% sea
plaque agarose (Cambrex) in RPMI supplemented with 10% FBS
on a semisolid bottom layer of growth medium containing 1%
agarose. Cells were fed once weekly with 0.3 mL of medium and
stained after 17 days with iodonitrotetrazolium (Sigma). The cells
containing Tet-off inducible DN-TCF4-GFP vector were grown
overnight in the presence or the absence of 100 ng/ml doxycycline, followed by extensive washing in PBS. The cells were then
counted and seeded in soft agarose dishes in the presence or the
absence of 100 ng/ml doxycyline. The remaining cells were grown
for one additional day with or without 100 ng/ml doxycyline, and

Antibodies, immunoblotting and immunoprecipitation
The following antibodies were purchased from commercial
sources: mouse anti-b-catenin, mouse anti-c-catenin (BD Biosciences), mouse anti-tubulin, mouse anti-Flag, mouse anti-HA
PLOS Genetics | www.plosgenetics.org
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PCR, and the expression of DN-TCF4 was assessed by immunoblot. Bcl-xL was used as a loading control. (E) The indicated mantle
cell lymphoma (MCL) cells were transduced with Top or Fop
luciferase reporter and a renilla luciferase virus, and the TCF/LEF
transcriptional activity was calculated by dividing the Top/renilla
ratio by the Fop/renilla ratio. Ramos and U937 cells were used as
positive and negative controls, respectively. (F) Lack of uncomplexed b-catenin in the MCL cells used in E, as measured by GSTTCF1 pull-down. Ovarian PA1 cells were used as positive control,
while Ramos and U937 cells were used as negative controls. (G)
Lack of uncomplexed b-catenin in primary hematopoietic tumors.
The type of tumor corresponding to each sample is indicated in
Figure 1G.
(PDF)

FACS analysis was performed to assess the level of induction of
DN-TCF4-GFP.

qPCR
Total RNA was extracted using the Trizol Reagent (Invitrogen),
incubated with DNase I (Invitrogen) and reverse transcribed in the
presence of random primers using SuperScript II reverse
transcriptase (Invitrogen) according to the manufacturer’s protocol. Quantitative PCR was performed using FastStart SYBR
Green Master (Roche) on a MJ Opticon (Bio-Rad). The primers
used for qPCR were: TATA Binding Protein (59-ATCAGTGCCGTGGTTCGT and 59-TTCGGAGAGTTCTGGGATTG), 18S (59-GTAACCCGTTGAACCCAT and 59-CCATCCAATCGGTAGTAG), Axin 2 (59-ACTGCCCACACGATAAGGAG and 59-CTGGCTATGTCTTTGGACCA), LEF1 (59CTTTATCCAGGCTGGTCTGC and 59-TCGTTTTCCACCATGTTTCA).

Figure S2 TCF1 expression triggers TCF/LEF reporter activity
in 293T cells. (A) 293T cells were co-transfected with the indicated
wild-type (T) or mutant (F) TCF/LEF reporters, the renilla
plasmid pRL-CMV and increasing amounts of TCF1 construct or
empty pcDNA3HA vector (500 ng). The TCF/LEF activity is
expressed as relative luciferase units normalized by the renilla
luciferase reading. (B) 293T cells were co-transfected with
SuperTop reporter, pBind renilla plasmid and HA-tagged TCF1
in the absence or the presence of ten-fold amount of HA-tagged
DN-TCF4. Two days after transfection, the cells were lysed,
followed by luciferase assay (lower panel) and immunoblot using
anti-HA antibody to assess the expression levels of TCF1 and DNTCF4 (upper panel). (C) Empty vector, TCF1, LEF1 or TCF4
constructs were co-transfected with SuperTop or SuperFop and
renilla luciferase plasmids in 293T cells and the Top/Fop ratio
was calculated.
(PDF)

Xenopus experiments
RNA was synthesized in vitro in the presence of cap analog
using the mMessage mMachine kit (Ambion). Microinjection,
explant dissection, cell culture and whole-mount antibody staining
were performed as described [71]. The 12/101 antibody
(Developmental Studies Hybridoma Bank, University of Iowa)
was used at a 1:1 dilution. Secondary antibody was a donkey antimouse IgG coupled to horseradish peroxidase (Jackson Laboratories), and was used at 1:1000 dilution. Color reactions were
performed using the Vector SG kit (Vector Laboratories). For RTPCR, Xenopus laevis embryos were staged and harvested at
appropriate stages according to morphological criteria. RNA
was prepared using RNA Bee RNA isolation reagent (Tel-Test
Inc.). RT-PCR was performed as described [72]. Primers used in
this study are as follows: Xbrachyury (59-GGATCGTTATCACCTCTG and 59-GTGTAGTCTGTAGCAGCA), chordin (59CAGTCAGATGGAGCAGGATC and 59-AGTCCCATTGCCCGAGTTGC), EF1-a (59-CAGATTGGTGCTGGATATGC
and 59-ACTGCCTTGATGACTCCTAG), Xnr3 (59-GTGAATCCACTTGTGCAGTT and 59-ACAGAGCCAATCTCATGTGC).
Studies on Xenopus laevis embryos were performed in accordance with the guidelines of the American Veterinary Medical
Association, and under the auspices of the Queens College
Institutional Animal Care and Use Committee (IACUC). All
experiments were undertaken with the highest regard for scientific,
ethical, and humane principles.

Figure S3 Lack of physical and functional interaction of
D21A;E29K mutant TCF1 (TCF1mt) with b-catenin or c-catenin.
(A) 293T cells were transfected as indicated with myc-tagged bcatenin and HA-tagged wild-type or mutant TCF1, followed by
immunoprecipitation using anti-myc antibody and immunoblot
with anti-myc or anti-HA antibodies. (B) Mel888 melanoma cells
containing a b-catenin mutation resulting in constitutive Wnt
activation were co-transfected with SuperTop reporter, the renilla
pRL-CMV plasmid and equal amounts of empty vector, TCF1,
d36TCF1 or TCF1mt. Two days after transfection, luciferase
assay was performed and the TCF/LEF reporter activity is
represented as renilla normalized relative luciferase units. (C)
293T cells were co-transfected with SuperTop reporter, the renilla
pRL-CMV plasmid, c-catenin and equal amounts of empty
vector, TCF1 or TCF1mt, followed by luciferase assay two days
after transfection.
(PDF)

Supporting Information
Endogenous TCF/LEF activation in hematopoietic
cancer cells. (A) K562 and U937 cells were transduced with wildtype (Top) or mutant (Fop) TCF/LEF lentiviral reporter driving the
expression of GFP, followed by FACS analysis. Breast MDAMB157
and lung H23 cells, which display constitutive autocrine Wnt
activation, were used as positive controls. (B) b-catenin or c-catenin
knockdown in K562 cells did not affect TCF/LEF activity. K562
cells containing Top or Fop luciferase lentiviral reporter were
transduced with b-catenin or c-catenin shRNAs, and the TCF/LEF
reporter activity was measured (lower panel). b-catenin and ccatenin down-regulation was assessed by immunoblot (upper panel).
(C) K562 cells were transduced with Top- or Fop-GFP lentiviral
reporter, followed by transduction with luciferase (control) or DNTCF4 lentiviruses. The GFP levels, corresponding to TCF/LEF
activation, were measured by FACS. (D) The mRNA levels of Lef1
and Axin 2 in the cells depicted in C were quantified by real-time

Figure S1

PLOS Genetics | www.plosgenetics.org

Figure S4 Exon IVa is not required for TCF1 transcriptional
activity. 293T cells were co-transfected with the SuperTop or
SuperFop reporter, the renilla plasmid pRL-CMV and the
indicated TCF1 or TCF4 constructs. Two days after transfection,
luciferase assay was performed and TCF/LEF activity expressed
as the Top/Fop ratio of the renilla normalized luciferase values.
(PDF)
Figure S5 aa 101–211 are involved in b-catenin-independent,
but not b-dependent, TCF1 transcriptional activity. (A) 293T cells
were co-transfected with the indicated SuperTop reporter, the
renilla plasmid pRL-CMV and the indicated TCF1 construct
followed two days later by luciferase assay. The TCF/LEF activity
is expressed as relative luciferase units normalized by the renilla
luciferase reading (lower panel). The expression of the different
11
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TCF1 constructs was assessed by immunoblot using the same cell
lysates (upper panel). (B) 293T cells were co-transfected with
SuperTop reporter, pRL-CMV and b-catenin (S33Y) with or
without the indicated TCF1 constructs, followed two days later by
luciferase assay.
(PDF)

transfected as indicated with Flag-tagged CREB5, HA-tagged
TCF1 and HA-tagged TCF4, followed by immunoprecipitation
using anti-Flag antibody and immunoblot with anti-HA or anti-Flag
antibodies.
(PDF)
Interaction between endogenous LEF1 and ATF2/7
in hematopoietic tumor cells. 2 mg of Lysate from K562 (A) or
Ramos (B) cells was immunoprecipitated using 10 ug of anti-LEF1
or control antibody, followed by immunoblot using the indicated
antibodies. The band corresponding to immunoprecipitated LEF1
(,55 kDa) was masked by the IgG heavy chain used for the
immunoprecipitation.
(PDF)

Figure S8

Figure S6 ATF2 synergizes with TCF1mt independently of b-

catenin. 293T cells were co-transfected with TCF1mt, ATF2 or
Wnt3a in combination with shRNA vectors targeting either
CHK1 (control), the three Dvl isoforms or b-catenin, in the
presence of the SuperTop reporter and the renilla plasmid pRLCMV. Three days after transfection, luciferase assay was
performed and TCF/LEF activity expressed as the mean +/2
SD of the renilla normalized luciferase values. The Wnt3a
construct was used to assess the efficiency of shDvl and shbcatenin in inhibiting Wnt canonical signaling.
(PDF)
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